## Sunday A Shoyele

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6155056/publications.pdf Version: 2024-02-01



SUNDAY A SHOVELE

#	Article	IF	CITATIONS
1	Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of Controlled Release, 2018, 281, 139-177.	9.9	377
2	Particle engineering techniques for inhaled biopharmaceuticals. Advanced Drug Delivery Reviews, 2006, 58, 1009-1029.	13.7	272
3	Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. International Journal of Pharmaceutics, 2006, 314, 1-8.	5.2	113
4	Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer. Molecular Carcinogenesis, 2016, 55, 743-756.	2.7	83
5	Synergistic anticancer action of quercetin and curcumin against tripleâ€negative breast cancer cell lines. Journal of Cellular Physiology, 2019, 234, 11103-11118.	4.1	81
6	Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. Expert Opinion on Drug Delivery, 2018, 15, 589-617.	5.0	74
7	Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer. Molecular Pharmaceutics, 2018, 15, 985-993.	4.6	39
8	Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 1402-1414.	7.0	34
9	Codelivery of Genistein and miRNA-29b to A549 Cells Using Aptamer-Hybrid Nanoparticle Bioconjugates. Nanomaterials, 2019, 9, 1052.	4.1	34
10	The Effects of Excipients and Particle Engineering on the Biophysical Stability and Aerosol Performance of Parathyroid Hormone (1-34) Prepared as a Dry Powder for Inhalation. AAPS PharmSciTech, 2011, 12, 304-311.	3.3	33
11	Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins. International Journal of Nanomedicine, 2016, Volume 11, 3533-3544.	6.7	33
12	Investigation of the Stability and Cellular Uptake of Self-Associated Monoclonal Antibody (MAb) Nanoparticles by Non-Small Lung Cancer Cells. Molecular Pharmaceutics, 2013, 10, 3275-3284.	4.6	23
13	Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation. Journal of Nanobiotechnology, 2015, 13, 61.	9.1	23
14	Self-Associated Submicron IgG1 Particles for Pulmonary Delivery: Effects of Non-ionic Surfactants on Size, Shape, Stability, and Aerosol Performance. AAPS PharmSciTech, 2013, 14, 200-210.	3.3	17
15	Influence of Surface Modification and the pH on the Release Mechanisms and Kinetics of Erlotinib from Antibody-Functionalized Chitosan Nanoparticles. Industrial & Engineering Chemistry Research, 2014, 53, 2987-2993.	3.7	15
16	Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model. Molecular Therapy - Nucleic Acids, 2016, 5, e282.	5.1	14
17	siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. Molecular Therapy - Nucleic Acids, 2017, 6, 259-268.	5.1	14
18	CD44-targeted, indocyanine green-paclitaxel-loaded human serum albumin nanoparticles for potential image-guided drug delivery. Colloids and Surfaces B: Biointerfaces, 2022, 209, 112162.	5.0	9

#	Article	IF	CITATIONS
19	Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. Molecular Pharmaceutics, 2018, 15, 1778-1790.	4.6	3